The estimated Net Worth of Kevin Bitterman is at least $41.1 Million dollars as of 9 October 2020. Mr. Bitterman owns over 13,000 units of Akero Therapeutics Inc stock worth over $301,804 and over the last 11 years he sold AKRO stock worth over $40,424,780. In addition, he makes $379,579 as Non-Executive Independent Director at Akero Therapeutics Inc.
Sign up
Mr. Bitterman AKRO stock SEC Form 4 insiders trading
Kevin has made over 13 trades of the Akero Therapeutics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 17,489 units of AKRO stock worth $459,611 on 1 June 2021.
The largest trade he's ever made was selling 1,000,000 units of Akero Therapeutics Inc stock on 22 May 2017 worth over $17,000,000. On average, Kevin trades about 137,730 units every 127 days since 2014. As of 9 October 2020 he still owns at least 11,780 units of Akero Therapeutics Inc stock.
You can see the complete history of Mr. Bitterman stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Kevin Bitterman biography
Kevin J. Bitterman Ph.D. serves as Non-Executive Independent Director of the Company. Dr. Bitterman currently serves as a partner at venture firm Atlas Venture, or Atlas, a venture capital firm, where he has been employed since June 2017 and where he focuses on investments in life science companies. Prior to joining Atlas in June 2017, Dr. Bitterman was a partner at Polaris Partners, an investment firm, as a member of the healthcare team since July 2004. Dr. Bitterman was also the founding CEO at Editas Medicine Inc., a pharmaceutical company, Visterra Inc., a biotechnology company, and Morphic Rock, LLC, a biotechnology company. During the past five years, Dr. Bitterman has served on the board of directors of Editas Medicine, Inc., Kala Pharmaceuticals, Inc., a pharmaceutical company, Genocea Biosciences, Inc., a biosciences company, as well as on the board of directors of several private companies. Dr. Bitterman also serves as board chair of the New England Venture Capital Association. Dr. Bitterman received a B.A. in biology from Rutgers College and a Ph.D. in genetics from Harvard Medical School.
What is the salary of Kevin Bitterman?
As the Non-Executive Independent Director of Akero Therapeutics Inc, the total compensation of Kevin Bitterman at Akero Therapeutics Inc is $379,579. There are 9 executives at Akero Therapeutics Inc getting paid more, with Andrew Cheng having the highest compensation of $5,431,810.
How old is Kevin Bitterman?
Kevin Bitterman is 43, he's been the Non-Executive Independent Director of Akero Therapeutics Inc since 2018. There are 13 older and 1 younger executives at Akero Therapeutics Inc. The oldest executive at Akero Therapeutics Inc is Dr. Timothy Rolph, 67, who is the Co-Founder & Chief Scientific Officer.
What's Kevin Bitterman's mailing address?
Kevin's mailing address filed with the SEC is C/O AKERO THERAPEUTICS, INC.,, 170 HARBOR WAY, 3RD FLOOR, SOUTH SAN FRANCISCO, CA, 94080.
Insiders trading at Akero Therapeutics Inc
Over the last 5 years, insiders at Akero Therapeutics Inc have traded over $146,260,704 worth of Akero Therapeutics Inc stock and bought 4,870,000 units worth $104,250,550 . The most active insiders traders include Group, Llc Green Jeremy Red..., Trust Blue Horizon Enterpri..., and G. Walmsley Graham. On average, Akero Therapeutics Inc executives and independent directors trade stock every 11 days with the average trade being worth of $1,642,344. The most recent stock trade was executed by Jonathan Young on 3 September 2024, trading 5,000 units of AKRO stock currently worth $133,600.
What does Akero Therapeutics Inc do?
akero therapeutics is developing best-in-class medicines that restore metabolic balance to treat non-alcoholic steatohepatitis (nash) and other serious metabolic diseases. akero's lead clinical program, akr-001, is a long-acting fc fusion modified fgf21 protein and potential best-in-class treatment for nash. akr-001 builds upon two decades of work on fgf21 biology. it is designed to affect both the liver and adipose tissue, reducing liver fat and suppressing inflammation and fibrosis.
What does Akero Therapeutics Inc's logo look like?
Complete history of Mr. Bitterman stock trades at Editas Medicine Inc, Genocea Biosciences Inc, and Akero Therapeutics Inc
Akero Therapeutics Inc executives and stock owners
Akero Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Andrew Cheng,
President, Chief Executive Officer, Director -
William White,
Chief Financial Officer, Executive Vice President and Head of Corporate Development -
Timothy Rolph,
Co-Founder, Chief Scientific Officer -
Jonathan Young,
Co-Founder, Chief Operating Officer, Executive Vice President -
Dr. Andrew Cheng,
Pres, CEO & Director -
Dr. Timothy Rolph,
Co-Founder & Chief Scientific Officer -
Dr. Jonathan M. Young,
Co-Founder, Exec. VP, COO & Sec. -
William R. White J.D.,
Exec. VP, CFO, Treasurer & Head of Corp. Devel. -
Mark Iwicki,
Independent Non-Executive Chairman of the Board -
Kevin Bitterman,
Non-Executive Independent Director -
Seth Harrison,
Non-Executive Independent Director -
Graham Walmsley,
Non-Executive Independent Director -
Kitty Yale,
Chief Development Officer -
Jane Henderson,
Non-Executive Independent Director -
Tomas Heyman,
Independent Director -
Kitty Yale,
Exec. VP & Chief Devel. Officer -
John J. Schembri,
VP of Fin. & Controller -
Venture Fund Xi, L.P. Atlas,
10% owner -
Trust Blue Horizon Enterpri...,
-
Venture Capital Vi, L.P.Ver...,
-
Group, Llc Green Jeremy Red...,
-
Global Strategic Fund Ii L....,
-
Venture Fund Xi, L.P.Atlas ...,
-
Aaron Royston,
Director -
Venture Capital Vi, L.P. Ve...,
10% owner -
Life Science Ventures, L.P....,
-
Venture Fund Xi, L.P.Atlas ...,
-
Venture Opportunity Fund I,...,
10% owner -
Chou Judy,
-
Catriona Yale,
Chief Development Officer -
Yuan Xu,
-
Scott A. Gangloff,
Chief Technology Officer -
Patrick Lamy,
Senior VP, Commercial Strategy